Evidence map›Paper›PMID 42056678›Full record

ArticleDiabetes, obesity & metabolism2026

High Prevalence of Metabolic Dysfunction-Associated Steatohepatitis With Significant Fibrosis in Primary Care and Endocrinology Clinics.

Srilaxmi Kalavalapalli, Eddison Godinez Leiva, Andrea Ortiz Rocha, Anu Sharma, Diana Barb, Nathaly Cuervo-Pardo, Kelly Y Chun, Toni R Prezant, Margery A Connelly, Jens T Rosenberg and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Diabetes, obesity & metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Srilaxmi KalavalapalliDivision of Endocrinology, Diabetes and Metabolism, Department of Medicine, University of Florida, Gainesville Florida, USA.
Eddison Godinez LeivaDivision of Endocrinology, Diabetes and Metabolism, Department of Medicine, University of Florida, Gainesville Florida, USA.
Andrea Ortiz RochaDivision of Endocrinology, Diabetes and Metabolism, Department of Medicine, University of Florida, Gainesville Florida, USA.
Anu SharmaDivision of Endocrinology, Diabetes and Metabolism, Department of Medicine, University of Florida, Gainesville Florida, USA.
Diana BarbDivision of Endocrinology, Diabetes and Metabolism, Department of Medicine, University of Florida, Gainesville Florida, USA.
Nathaly Cuervo-PardoDivision of Endocrinology, Diabetes and Metabolism, Department of Medicine, University of Florida, Gainesville Florida, USA.
Kelly Y ChunLabcorp, Calabasas, California, USA.
Toni R PrezantLabcorp, Calabasas, California, USA.
Margery A ConnellyLabcorp, Morrisville, North Carolina, USA.
Jens T RosenbergAdvanced Magnetic Resonance Imaging and Spectroscopy Facility, McKnight Brain Institute, University of Florida, Gainesville, Florida, USA.
Joseph R GrajoDepartment of Radiology, University of Florida College of Medicine, Gainesville, Florida, USA.
Fernando BrilDivision of Endocrinology, Diabetes and Metabolism, University of Alabama, Birmingham, USA.ORCID 0000-0001-5570-4396
Kenneth CusiDivision of Endocrinology, Diabetes and Metabolism, Department of Medicine, University of Florida, Gainesville Florida, USA.ORCID 0000-0002-8629-418X

Funding

NIH HHS DK-120331
6 · The paper itself

Abstract

aimsMetabolic dysfunction-associated steatohepatitis (MASH) is a leading cause of cirrhosis. NIS2+ is a recently approved serum-based test combining two biomarkers (miR-34a-5p and YKL-40) to identify at-risk MASH (i.e., MASH and significant fibrosis).

objectiveTo assess the prevalence of at-risk MASH by NIS2+ in individuals from primary care or endocrinology clinics. MATERIALS AND

methods798 participants recruited from outpatient clinics were risk-stratified by NIS2+ into low-risk, intermediate-risk or having at-risk MASH (NIS2+ score < 0.46, ≥ 0.46 and < 0.68 or ≥ 0.68, respectively). Presence of steatosis (CAP ≥ 288 dB/m) and clinically significant liver fibrosis (VCTE- ≥ 8.0 kPa) was established by transient elastography (FibroScan).

resultsAt-risk MASH affected 29% of individuals with both obesity and T2D compared to 3% of those without either condition (p < 0.001). People with at-risk MASH, compared to those at low-risk, more often had steatosis (81% vs. 40%), clinically significant fibrosis (42% vs. 5%), AST or ALT ≥ 40 IU/L, hepatic insulin resistance (by HOMA-IR) and adipose tissue insulin resistance (by adipo-IR) (all p < 0.001). NIS2+ strongly correlated with diagnosis of at-risk MASH by FAST (r = 0.67; p < 0.001), as well as CK-18, ALT and AST and liver fibrosis by VCTE-LSM (all p < 0.001).

conclusionThe prevalence of at-risk MASH is high in individuals with obesity and T2D attending outpatient primary care and endocrinology clinics. Their progression to cirrhosis may be prevented with early risk-stratification and timely intervention.

Indexed as

Fatty LiverLiver CirrhosisNon-alcoholic Fatty Liver DiseaseAdultAgedAmbulatory Care FacilitiesBiomarkersChitinase-3-Like Protein 1Cross-Sectional StudiesDiabetes Mellitus, Type 2EndocrinologyFemaleHumansMaleMicroRNAsMiddle AgedBiomarkersCHI3L1 protein, humanChitinase-3-Like Protein 1MicroRNAsMIRN34 microRNA, humanliver fibrosisMASHMASLDmetabolic dysfunction‐associated steatohepatitismetabolic dysfunction‐associated steatotic liver diseaseNIS2+obesityT2Dtype 2 diabetesVCTE‐LSM

Identifiers

PMID42056678
PMCPMC13243976

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.